Christopher Moreau, CEO of UF startup Algernon Pharmaceuticals, a clinical-stage pharmaceutical development company, joins Steve Darling from Proactive Vancouver to provide an update about its initiated phase 2 clinical study of NP-120 for COVID-19 on infected patients in South Korea.
Related news:
Algernon Submits for Ethics Approval for Phase 2 IPF and Chronic Cough Study. Algernon Appoints Novotech As CRO for Phase 2 Coronavirus Ifenprodil Trial. Algernon Announces Filing of U.S. FDA Pre-Ind Meeting Request for Ifenprodil Coronavirus Trial, Expanded Access, and Emergency Use. Algernon Explores the Use of NP-120 (Ifenprodil) as a Novel Treatment for Coronavirus.
